Gene therapy aims to tame rare immune disorder

NCT ID NCT07697118

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial tests a new gene therapy called FOXP3-T4 for people with IPEX syndrome, a rare genetic condition that causes severe immune problems. The therapy involves taking a patient's own immune cells, modifying them in the lab to work better, and giving them back via a single infusion. Some participants may also receive low-dose IL-2 to boost the therapy. The goal is to stabilize symptoms and reduce the need for lifelong immune-suppressing drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FOXP3-T4 (gene-modified immune cells) and low-dose IL-2
What this could lead to
If successful, this could provide a long-term treatment option for IPEX syndrome, potentially allowing patients to reduce or stop immunosuppressive drugs.
What could go wrong
This is an early-phase trial with only 5 participants, so results may not apply broadly. Risks include immune reactions, lymphoproliferation, or the therapy not working as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THE IMMUNE DYSREGULATION POLYENDOCRINOPATHY ENTEROPATHY X-LINKED SYNDROME IS A PRIMARY IMMUNODEFICIENCY CAUSED BY PATHOGENIC VARIANTS IN FORKHEAD BOX PROTEIN 3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Biotherapy, Hopital Necker Enfants malades

    Paris, Île-de-France Region, 75015, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••